MSL2

Across TCGA pan-cancer cohorts, MSL2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MSL2 data layer compared with 30 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MSL2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MSL2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and UCEC are the cancer types where MSL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	1.000	0.336	.008	18	view →
LUAD	OS	Tertile	III,IV	0.867	0.317	.002	16	view →
UCEC	DFS	Median	All	0.855	0.945	.040	10	view →
LSCC	DFS	Tertile	III,IV	1.000	0.493	.025	2	view →
HNSC	OS	Tertile	All	0.679	0.938	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MSL2–CCRCC (DFS)

Open the CCRCC breakdown →